MDGL
MadrigalFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Successful late‑stage readouts and smooth regulatory/commercial execution could re-rate the stock dramatically from the current anchor, driven by high-margin hepatic franchise and limited direct competition.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Clinical readout misses endpoints or is inconclusive
Momentum
41
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.90 · Bull $7.25 · Bear $0.73
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-16 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $678.93
Why
Momentum41 · Δ7d -2.8
Value41 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
41
26% active weight
Current posture
7d trendFlat
Δ7d
-2.8
Δ21d
-8.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 41.4 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$12.35B
Beta
-1.02
Shares Out
23.06M
P/E (TTM) · Derived
-41.7
P/S (TTM)
18.04
P/FCF (TTM) · Derived
-51.84
Rev YoY
+126.8%
EPS YoY
-1.9%
Gross Margin
+92.9%
Op Margin
-41.9%
Net Debt
-$641.02M
Current Ratio
3.50
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology